Accelerating the Development and Improving Access to CAR and TCR engineered T cell therapy

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.

€ 192,000

January 2021 - December 2025 (5 years)



Academisch Medisch Centrum Bij De Universiteit Van Amsterdam (AMC), Netherlands

Bayer Aktiengesellschaft (Bayer), Germany

Biosci Consulting Bvba (Biosci), Belgium

Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel (PEI), Germany

Consorci Institut D’investigacions Biomediques August Pi I Sunyer (Idibaps), Spain

Erasmus Universiteit Rotterdam (Eshpm), Netherlands

European Cancer Patient Coalition (ECPC), Belgium

Forschung E.V. (Fraunhofer), Germany

Fraunhofer Gesellschaft Zur Foerderung Der Angewandten

Fundacio Privada Institut De Recerca De L’hospital De La Santa Creu I Sant Pau (Ir-Hscsp), Spain

Information Technology For Translational Medicine (ITTM) Sa (ITTM), Luxembourg

Institut National De La Sante Et De La Recherche Medicale (INSERM), France

Institut National Du Cancer Gip, France

Janssen Pharmaceutica Nv (Janssen), Belgium

Medizinische Universitaet Wien (MUW), Austria

Miltenyi Biotec Bv & Co Kg (Mb), Germany

Ospedale Pediatrico Bambino Gesu (OPBG), Italy

T-Curx Gmbh (T-Curx) Germany

Technische Universitaet Muenchen (Tum), Germany

Universidad De Navarra (UNAV), Spain

Universita Vita-Salute San Raffaele (USR), Italy

University College London (UCL), UK

Why it matters

The aim of the project T2EVOLVE is to build a sustainable innovation ecosystem that will support the development of advance engineered T cell therapy to a level where every European cancer patient in need has access to safe and effective T cell products. How? The optimization of preclinical models, analytical monitoring, lymphodepletion regimens will enhance the development of safer and more effective engineered T cell therapies by reducing the toxicity observed in clinical trials and improve the success rate of clinical trials. A strategic aim of the project is to take an advantage on the tremendous potential that exists in Europe and close the gap in clinical and commercial translation in order to bring the EU back to the forefront of this global movement.

What ECPC does

ECPC will assist the T2EVOLVE project by engaging in patient involvement in the R&D process, co-development of patient friendly communication tools to improve the patient journey (M4-60)
co-development of tools and materials to help HCPs better respond to patient needs, patient-centered Health Technology Assessment of engineered T cell therapy and the creation of a roadmap for engineered T-cell therapy (online white paper).






This project is funded by the European Union.